(LLYX) Defiance Daily Target 2X - NYSE
ETF Category: Trading--Leveraged Equity | Exchange: NYSE (USA) | Market Cap: 63m USD | Total Return: 57.1% in 12m
Avg Turnover: 11.8M
Warnings
Choppy
Tailwinds
Supp Ema20, Rs Leader
The Defiance Daily Target 2X Long LLY ETF (LLYX) is an actively managed, non-diversified fund designed to provide 200% of the daily price performance of Eli Lilly and Company. To achieve this leveraged exposure, the fund utilizes financial derivatives including swap agreements and listed options contracts.
The underlying security, Eli Lilly, operates within the pharmaceutical sector, a capital-intensive industry driven by long-term research and development cycles and patent protections. This business model relies on a pipeline of branded medications to maintain market share against generic competition.
Investors can evaluate the historical volatility and fundamental valuation of the underlying stock at ValueRay. Because this ETF targets daily returns, the effects of compounding may cause performance to deviate significantly from the 2x target over periods longer than a single trading session.
- GLP-1 drug demand drives Zepbound and Mounjaro revenue growth
- Manufacturing capacity expansion dictates supply volume and market share
- Medicare coverage policies and pricing negotiations impact net margins
- Competitive pressure from oral weight-loss drug clinical trial results
As of June 12, 2026, the stock is trading at USD 26.25 with a total of 452,546 shares traded.
Over the past week, the price has changed by +6.02%,
over one month by +41.74%,
over three months by +26.26% and
over the past year by +57.07%.
Defiance Daily Target 2X has no consensus analysts rating.